

=> d his

(FILE 'HOME' ENTERED AT 14:49:01 ON 09 AUG 2005)

FILE 'REGISTRY' ENTERED AT 14:52:51 ON 09 AUG 2005
E TIOTROPIUM/CN

L1 1 S E3
L2 10 S E3-E12

FILE 'CAPLUS' ENTERED AT 14:53:34 ON 09 AUG 2005
230 S L2 OR TIOTROPIUM

L3

FILE 'REGISTRY' ENTERED AT 14:53:58 ON 09 AUG 2005
E SALMETEROL/CN

L4 5 S E3-E8

FILE 'CAPLUS' ENTERED AT 14:54:26 ON 09 AUG 2005

L5 1033 S L4 OR SALMETEROL
L6 30 S L3(L)L5
L7 0 S L6 NOT PY>=2000

FILE 'USPATFULL, USPAT2' ENTERED AT 15:16:14 ON 09 AUG 2005
329 S L6

L8

=>

=> e tiotropium

E1	1	TIOTRIFAR/BI
E2	8	TIOTROP/BI
E3	8 -->	TIOTROPIUM/BI
E4	1	TIOV/BI
E5	1	TIOVAL/BI
E6	1	TIOVALON/BI
E7	3	TIOVEIL/BI
E8	1	TIOVEL/BI
E9	2	TIOVIT/BI
E10	1	TIOVIVO/BI
E11	2	TIOW/BI
E12	1	TIOWEN/BI

=> s e3

L1 8 TIOTROPIUM/BI

=> d rn str cn 1-8

L1 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN

RN 412010-64-1 REGISTRY


CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, (1 α ,2 β ,4 β ,5 α ,7 β .bet a.)-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:


CN **Tiotropium p-toluenesulfonate**

CM 1

Relative stereochemistry.



CM 2



L1 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN

RN 412010-63-0 REGISTRY


CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, (1 α ,2 β ,4 β ,5 α ,7 β .bet a.)-, methyl sulfate (salt) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Tiotropium methylsulfate**

CM 1

Relative stereochemistry.



CM 2

Me-O-SO₃⁻

L1 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN

RN 412010-62-9 REGISTRY


CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, (1 α ,2 β ,4 β ,5 α ,7 β), methanesulfonate (salt) (9CI) (CA INDEX NAME)

OTHER NAMES:


CN **Tiotropium methanesulfonate**

CM 1

Relative stereochemistry.




CM 2



L1 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN
RN 412010-61-8 REGISTRY

Relative stereochemistry.



● I⁻


CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, iodide, (1 α ,2 β ,4 β ,5.alpha.a.,7 β)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN **tiotropium iodide**

L1 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN
RN 412010-60-7 REGISTRY

Relative stereochemistry.



● Cl⁻

CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-

thienylacetyl)oxy]-9,9-dimethyl-, chloride, (1 α ,2 β ,4 β ,5 α ,1
pha.,7 β)- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN **tiotropium chloride**

L1 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN

RN 411207-31-3 REGISTRY

Relative stereochemistry.



● Br⁻

● H₂O

CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide, monohydrate, (1 α ,2 β ,4 β ,5 α ,7 β)- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN **Tiotropium bromide monohydrate**

L1 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN

RN 186691-13-4 REGISTRY

Relative stereochemistry.




CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, (1 α ,2 β ,4 β ,5 α ,7 β)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Tiotropium**

Relative stereochemistry.



● Br⁻

CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide, (1 α ,2 β ,4 β ,5.alpha.,7 β)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Oxa-9-azatricyclo[3.3.1.0^{2,4}]nonane, 3-oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane deriv.

OTHER NAMES:

CN BA 679BR

CN Spiriva

CN tiotropium

CN **Tiotropium bromide**

=> e salmeterol

E1	1	SALMETEDUR/BI
E2	11	SALMETER/BI
E3	11 -->	SALMETEROL/BI
E4	2	SALMF/BI
E5	2	SALMFAMIDE/BI
E6	16	SALMI/BI
E7	1	SALMIAC/BI
E8	1	SALMID/BI
E9	1	SALMIDE/BI
E10	1	SALMIDO/BI
E11	1	SALMIDOCHOL/BI
E12	9	SALMINE/BI

=> s e3

L2 11 SALMETEROL/BI

=> d rn str cn 1-11

L2 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 384849-80-3 REGISTRY


CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (α 1R)-, acetate (salt) (9CI) (CA INDEX NAME)

OTHER NAMES:


CN **(R)-Salmeterol acetate**

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L2 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 384849-79-0 REGISTRY


CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (α 1S)-, acetate (salt) (9CI) (CA INDEX NAME)

OTHER NAMES:


CN (S)-Salmeterol acetate

CM 1

Absolute stereochemistry.



CM 2



L2 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 136112-02-2 REGISTRY

CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6 α ,11 β ,16 α ,17 α)-, mixt. with 4-hydroxy- α 1-

[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
1-hydroxy-2-naphthalenecarboxylate (salt) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (\pm)-, 1-hydroxy-2-naphthalenecarboxylate (salt), mixt. contg.
- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 1-hydroxy-2-naphthalenecarboxylate (salt), mixt. contg. (9CI)
- CN 2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with (\pm)-4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol, mixt. contg.
- CN 2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol, mixt. contg. (9CI)
- CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6 α ,11 β ,16 α ,17 α)-, mixt. with (\pm)-4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylate (salt)

OTHER NAMES:

- CN **Fluticasone propionate mixt. with salmeterol 1-hydroxy-2-naphthoate (salt)**
- CN SAS 40023


CM 1

Absolute stereochemistry.




CM 2

CM 3




CM 4




L2 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 135271-49-7 REGISTRY
 CN 2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with (α1R)-4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (α1R)-, 1-hydroxy-2-naphthalenecarboxylate (salt) (9CI)
 OTHER NAMES:
 CN (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt

CM 1

Absolute stereochemistry. Rotation (-).




CM 2



L2 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 135271-48-6 REGISTRY

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (α 1S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (S)-


OTHER NAMES:

CN **(S)-Salmeterol**

L2 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 135271-47-5 REGISTRY

Absolute stereochemistry. Rotation (-).



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (α 1R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (R)-

OTHER NAMES:

CN **(R)-Salmeterol**

CN **R-(-)-Salmeterol**

L2 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 94749-10-7 REGISTRY

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (\pm)-, sulfate (2:1) (salt)


OTHER NAMES:

CN **Salmeterol sulfate**

CM 1



CM 2



L2 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 94749-08-3 REGISTRY

CN 2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy- α 1-
[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1) (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (\pm)-, 1-hydroxy-2-naphthalenecarboxylate (salt)

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 1-hydroxy-2-naphthalenecarboxylate (salt) (9CI)

CN 2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with (\pm)-4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)

OTHER NAMES:

CN Arial

CN GR 33343G

CN GR 3343G

CN Salmatedur

CN **Salmeterol hydroxynaphthoate**

CN **Salmeterol xinafoate**


CN Serevent

CN Serevent Diskus


CN Siduomi

CN SN 408

CM 1



CM 2



L2 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 94749-06-1 REGISTRY

CN Benzoic acid, 4-chloro-, compd. with 4-hydroxy- α 1-[[[6-(4-

phenylbutoxy)hexyl]amino)methyl]-1,3-benzenedimethanol (1:1) (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-, (\pm)-, 4-chlorobenzoate (salt)
- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-, 4-chlorobenzoate (salt) (9CI)
- CN Benzoic acid, 4-chloro-, compd. with (\pm)-4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-1,3-benzenedimethanol (1:1)


OTHER NAMES:

CN **Salmeterol 4-chlorobenzoate**

CM 1



CM 2



L2 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN

RN 94749-05-0 REGISTRY

- CN Benzoic acid, 2-hydroxy-, compd. with 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-1,3-benzenedimethanol (1:1) (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:


- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-, (\pm)-, 2-hydroxybenzoate (salt)
- CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-, 2-hydroxybenzoate (salt) (9CI)
- CN Benzoic acid, 2-hydroxy-, compd. with (\pm)-4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino)methyl]-1,3-benzenedimethanol (1:1)

OTHER NAMES:


CN **Salmeterol salicylate**

CM 1





L2 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 89365-50-4 REGISTRY



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- α 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (\pm)-

OTHER NAMES:

CN GR 33343X

CN **Salmeterol**

=> FIL CAPLUS

L6 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:242164 CAPLUS
 DOCUMENT NUMBER: 138:260474
 TITLE: Inhalant compositions containing **tiotropium**
 salts and **salmeterol** salts with low
 solubility
 INVENTOR(S): Linz, Guenter; Soyka, Rainer
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10145438	A1	20030403	DE 2001-10145438	20010914
DE 10209243	A1	20030918	DE 2002-10209243	20020304
US 2003130300	A1	20030710	US 2002-235410	20020905
US 6919325	B2	20050719		
CA 2459493	AA	20030327	CA 2002-2459493	20020906
EP 1429768	A1	20040623	EP 2002-777013	20020906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504076	T2	20050210	JP 2003-528548	20020906
US 2003069310	A1	20030410	US 2002-242249	20020912
US 6680345	B2	20040120		
CA 2477714	AA	20030912	CA 2003-2477714	20030219
EP 1483231	A1	20041208	EP 2003-717188	20030219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519110	T2	20050630	JP 2003-572941	20030219
PRIORITY APPLN. INFO.:				
			DE 2001-10145438	A 20010914
			DE 2002-10209243	A 20020304
			DE 2002-10216124	A 20020412
			DE 2002-10216125	A 20020412
			US 2002-386172P	P 20020605
			US 2002-387060P	P 20020607
			WO 2002-EP9974	W 20020906
			WO 2003-EP1644	W 20030219

Handwritten notes:
 - "clan" written next to CA 2459493
 - "OPF clan 0-12" written with an arrow pointing to JP 2005519110

REFERENCE COUNT:

ACCESSION NUMBER: 2003:242155 CAPLUS
 DOCUMENT NUMBER: 138:254957
 TITLE: Preparation of salicylic acid salts of salmeterol as β -mimetics
 INVENTOR(S): Linz, Guenter; Soyka, Rainer; Steiner, Andre
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024440	A1	20030327	WO 2002-EP9975	20020906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10145438	A1	20030403	DE 2001-10145438	20010914
DE 10216125	A1	20031030	DE 2002-10216125	20020412
US 2003130300	A1	20030710	US 2002-235410	20020905
US 6919325	B2	20050719		
CA 2460440	AA	20030327	CA 2002-2460440	20020906
EP 1429751	A1	20040623	EP 2002-764875	20020906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504798	T2	20050217	JP 2003-528537	20020906
US 2003069310	A1	20030410	US 2002-242249	20020912
US 6680345	B2	20040120		
PRIORITY APPLN. INFO.:			DE 2001-10145438	A 20010914
			DE 2002-10216125	A 20020412
			DE 2002-10209243	A 20020304
			US 2002-386172P	P 20020605
			US 2002-387060P	P 20020607
			WO 2002-EP9975	W 20020906
OTHER SOURCE(S):	MARPAT	138:254957		
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L6 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS
DOCUMENT NUMBER: 136:374855
TITLE: Inhalant compositions containing **tiotropium**
salts and **salmeterol** salts
INVENTOR(S): Schmelzer, Christel; Nagel, Juergen
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
CA 2429012	AA	20020516	CA 2001-2429012	20011109
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
EP 1335728	B1	20050323		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
EP 1514546	A1	20050316	EP 2004-28508	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 291428	E	20050415	AT 2001-989446	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
ZA 2003002921	A	20040419	ZA 2003-2921	20030414
BG 107781	A	20040630	BG 2003-107781	20030508
NO 2003002111	A	20030708	NO 2003-2111	20030512
JP 2005068163	A2	20050317	JP 2004-355226	20041208
PRIORITY APPLN. INFO.:			DE 2000-10056104	A 20001113
			US 2000-251603P	P 20001206
			EP 2001-989446	A3 20011109
			JP 2002-540737	A3 20011109
			WO 2001-EP12962	W 20011109

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:867964 CAPLUS
DOCUMENT NUMBER: 135:376803
TITLE: Stable pharmaceutical solution formulations for pressurized metered dose inhalers
INVENTOR(S): Lewis, David; Ganderton, David; Meakin, Brian; Brambilla, Gaetano; Ferraris, Alessandra
PATENT ASSIGNEE(S): Chiesi Farmaceutici S.P.A., Italy
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1157689	A1	20011128	EP 2001-112230	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2411047	AA	20011129	CA 2000-2411047	20000522
WO 2001089480	A1	20011129	WO 2000-EP4635	20000522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000015884	A	20030708	BR 2000-15884	20000522
JP 2003534266	T2	20031118	JP 2001-585725	20000522
EE 200200649	A	20040615	EE 2002-649	20000522
EP 1466594	A2	20041013	EP 2004-11423	20010518
EP 1466594	A3	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002025299	A1	20020228	US 2001-860689	20010521
US 6716414	B2	20040406		
BG 107256	A	20030630	BG 2002-107256	20021108
NO 2002005568	A	20021120	NO 2002-5568	20021120
US 2004047809	A1	20040311	US 2003-640005	20030814
PRIORITY APPLN. INFO.:			WO 2000-EP4635	A 20000522
			EP 2001-112230	A3 20010518
			US 2001-860689	A1 20010521
REFERENCE COUNT:	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		